Right ventricular (RV) failure in pulmonary arterial hypertension is associated with adrenergic activation. Clinicians are often confronted with two questions: (1) Which is the optimal inotrope in RV failure? (2) Is there a long-term role for modulating the adrenergic system? In left ventricular failure, G proteincoupled receptor kinase-2 (GRK2) mediates adrenergic receptor downregulation/desensitization, and GRK2 inhibitors improve adrenergic signaling and function. We explored the molecular basis and therapeutic relevance of adrenergic abnormalities in RV failure and RV hypertrophy (RVH). Using human tissues and rodent models (of maladaptive and adaptive-RVH), we show that
Summary-Among the intracellular signaling pathways involved in the regulation of cardiac hypertrophy, class II histone deacetylases (HDACs) have been identified as important signal-responsive repressors for cardiac hypertrophy. Little is known about the regulation of HDAC4 in response to extracellular stimuli leading to cardiac hypertrophy. Here we identified casein kinase-2 interacting protein-1 (CKIP-1) as a novel regulator of pathological cardiac hypertrophy and class II HDACs/myocyte enhancer factor-2 signaling in cardiac myocytes. In this research, our data showed that CKIP-1 is induced early after pressure overload, but sharply reduced in the late phases of cardiac hypertrophy in mouse and human hearts. CKIP-1 systemically deficient mice exhibit spontaneous pathological cardiac hypertrophy by 8 months and display exaggerated responses to pressure overload. Conversely, cardiac specific overexpression of CKIP-1 attenuates pathological remodeling during chronic pressure overload. HDAC4 was identified to be a CKIP-1 interaction partner through unbiased interaction screening. HDAC4 is involved in the regulation of myocyte enhancer factor-2 transcription activity via decreasing the phosphorylation of HDAC4. CKIP-1 could increase the association of HDAC4 with protein phosphatase 2A and promote the dephosphorylation of HDAC4. These results demonstrated that CKIP-1 was required to inhibit the occurrence of cardiac hypertrophy and represented a promising candidate target for preventing hypertrophic cardiomyopathy.
Conclusions-CKIP-1 was found to be an inhibitor of cardiac hypertrophy by upregulating the dephosphorylation of HDAC4 through the recruitment of protein phosphatase 2A. These results demonstrated a unique function of CKIP-1, by which it suppresses cardiac hypertrophy through its capacity to regulate HDAC4 dephosphorylation and fetal cardiac genes expression. 1
Neutrophil-Derived Matrix Metalloproteinase 9 Triggers Acute Aortic Dissection
Summary-Acute aortic dissection (AAD) is a potentially fatal vascular disease, and prompt diagnosis and treatment by timely surgery are required for survival of the patients. No efficient biomarkers are available for diagnosis of AAD prior to determination of the disease by computed tomography. Medial degeneration is known as an important risk factor for the development of AAD; however, the emergent nature of the disease and the paucity of animal models prevent us from studying the molecular mechanisms for triggering the disease. We found that matrix metalloproteinase 9 (MMP9) and angiotensin II were increased significantly in blood samples from AAD patients compared with those from normal subjects and the patients with nonruptured aortic aneurysm. This was accompanied by enhanced infiltrations of MMP9-producing neutrophils in the dissected aortas. Based on the data, we established a mouse model of AAD, which was induced by infusion of angiotensin II to mice pretreated with β-aminopropionitrile monofumarate (a lysyl oxidase inhibitor). All mice exhibited AAD within 24 hours after angiotensin II infusion. Aortic tissue from the AAD mice showed enhanced expression and activity of MMP9, and MMP9immunoreactive neutrophils were infiltrated in both dissected media and intima of nondissected lesions. Genetic depletion or pharmaceutical inhibition of MMP9 and neutrophil ablation attenuated the AAD incidence. These data demonstrate that neutrophilderived MMP9 is responsible for triggering AAD in this model. Taken together, MMP9 could serve as a potential biomarker for diagnostic screening of AAD, and administration of angiotensin II receptor blockers or MMP9 inhibitors could be effective therapeutic approaches to AAD.
Conclusions-These data suggest that AAD is initiated by neutrophils that have infiltrated the aortic intima and released MMP9 in response to angiotensin II. 2 Summary-Endothelial barrier dysfunction is a major contributor to morbidity and mortality in the critically ill. Loss of the endothelial barrier follows exposure of the endothelium to inflammatory mediators and drives vascular leakage and edema formation. To date endothelial barrier function and vascular leakage still lack appropriate therapy. This study shows that imatinib-an US Food and Drug Administration-approved tyrosine kinase inhibitordirectly protects the endothelial barrier under inflammatory conditions. With the use of endothelial cells isolated from various vascular beds, it was shown that imatinib attenuates the loss of endothelial barrier on stimulation with inflammatory mediators. Imatinib protects against endothelial barrier dysfunction predominantly by inhibition of the tyrosine kinase Abl-related gene (Arg), a novel mediator of endothelial barrier disruption. The effect of imatinib on endothelial barrier was established in various mouse models of vascular leakage. Notably, imatinib attenuated vascular leakage in a murine model of sepsis, even when imatinib treatment was initiated considerable time after induction of sepsis. This study carries important clinical implications. First, imatinib may form a suitable therapy for treatment of diseases characterized by vascular leakage. The longstanding experience with imatinib, together with the fact that imatinib concentrations used in this study parallel plasma values in cancer patients, are apparent advantages in this case. Logical first steps in further development of imatinib involve Phase I and II trials to evaluate safety and efficacy of imatinib in patients with profound vascular leakage. Second, the identification of Arg as a novel and drugable target opens perspectives for more specific pharmaceutical interventions.
Conclusions-Thus, imatinib prevents endothelial barrier dysfunction and edema formation via inhibition of Arg. These findings identify imatinib as a promising approach to permeability edema and indicate Arg as novel target for edema treatment. 4 
Exosomes Mediate the Cytoprotective Action of Mesenchymal Stromal Cells on Hypoxia-Induced Pulmonary Hypertension
Summary-Pulmonary arterial hypertension remains without cure despite significant progress in our understanding of its pathophysiology. Given the complex molecular and cellular pathways underlying the development of pulmonary arterial hypertension, therapies aimed at multiple pathways and cellular targets may prove to be more efficacious. Stem cell-based therapies hold such a promise because they can simultaneously target diverse signaling pathways and have long-lasting effects. Accumulating studies support an important cytoprotective, antiinflammatory role for mesenchymal stem cells with demonstrated efficacy against pulmonary hypertension in animal models of disease. We previously reported both prevention and reversal of severe pulmonary hypertension and right heart failure in a mouse model of hypoxia-induced pulmonary hypertension and have postulated a paracrine mode of mesenchymal stem cell protective functions. In this report, we show that mesenchymal stem cells secrete microvesicles (exosomes), which are the vectors of their action, being both necessary and sufficient to confer cytoprotection on the lung vasculature. We show that, potentially through epigenetic mechanisms involving microRNA signaling, mesenchymal stromal cell exosome preparations can have long-lasting therapeutic effects on pulmonary hypertension. These findings may lead to the development of alternative strategies in the field of stem cell-based therapies, at least for certain lung diseases, in that delivery of in vitro purified exosomes could substitute for the delivery of intact cells. Exosome treatment, in addition to its enhanced practicality in terms of storage and administration, does not carry the danger of oncogenic potential of donor cells, an important consideration in all stem cell-based therapies.
Conclusions-This study indicates that mesenchymal stromal cellderived exosomes exert a pleiotropic protective effect on the lung and inhibit pulmonary hypertension through suppression of hyperproliferative pathways, including signal transducer and activator of transcription 3-mediated signaling induced by hypoxia. 5
Oxysterol-Induced Soluble Endoglin Release and Its Involvement in Hypertension
Summary-Preeclampsia is one of the most severe complications of pregnancy. Characterized by systemic hypertension, proteinuria, and edema in the third trimester of pregnancy, preeclampsia is responsible for the highest rates of morbidity and mortality for both pregnant women and neonates in the developed world. Treatment of hypertension in preeclampsia is especially needed because of the absence of effective therapies except for the delivery of the baby and placenta. Hypoxia in the placenta is considered a key event in the pathogenesis of preeclampsia, whereas soluble endoglin (sEng) is a prognostic marker and plays a pathogenic role. In this article, we report that the hypoxia-dependent cholesterol derivatives oxysterols, via the liver X receptors, are able to increase sEng levels in vitro and in vivo by a mechanism involving activation of matrix metalloproteinase-14. Interestingly, mice treated with oxysterols or liver X receptor agonists underwent an increase in plasmatic sEng levels and an augmentation of arterial pressure. In addition, administration of an endoglin fragment containing the matrix metalloproteinase-14 cleavage site prevented the oxysterol-dependent increase in arterial pressure and sEng levels in mice. These data reveal for the first time the involvement of the liver X receptor pathway in sEng release and its contribution to vascular homeostasis. They also suggest that administration of endoglin peptides in preeclamptic women might serve to counteract the pathogenic effect of the elevated circulating sEng. Further
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Conclusions-These studies provide a clue to the involvement of the liver X receptor pathway in soluable endoglin release and its pathogenic role in vascular disorders such as preeclampsia. 6
Endogenous and Natural Complement Inhibitor Attenuates Myocardial Injury and Arterial Thrombogenesis
Summary-Reperfusion of ischemic tissues induces tissue injury that is mediated by complement activation. We have identified a novel, endogenous, natural complement inhibitor that displaces the 3 serine proteases (ie, mannose-binding lectin/ficolin-associated serine protease-1, -2, and -3) from the mannose-binding lectin complex in a dose-dependent manner. Furthermore, at pharmacologic concentrations, mannose-binding lectin-associated protein-1 prevents arterial thrombogenesis, as well as myocardial injury after ischemia and reperfusion in vivo. The mannose-binding lectin complex has been associated with several clinical diseases, and mannose-binding lectinassociated protein-1 may represent a novel molecular mechanism to modulate its activity in vivo.
Conclusions-Our results suggest that the natural, endogenous inhibitor mannose-binding lectin (MBL)/ficolin-associated protein-1 (MAP-1) effectively inhibits lectin pathway activation in vivo. MAP-1 at pharmacological doses represents a novel therapeutic approach for human diseases involving the lectin pathway and its associated MBL/ ficolin-associated serine protease (MASP). 7
Rho-Associated Coiled-Coil-Containing Kinase 2 Deficiency in Bone Marrow-Derived Cells Leads to Increased Cholesterol Efflux and Decreased Atherosclerosis
Summary-The retention of modified cholesterol by macrophages and their development into foam cells are critical steps in atherogenesis. Cholesterol retention in macrophages is governed by cholesterol uptake and efflux. The precise signaling pathways that regulate cholesterol uptake and efflux are not known. The Rho-associated coiled-coil-containing kinases (ROCK1 and ROCK2) are serinethreonine protein kinases that are involved in the regulation of the actin cytoskeleton. Recent studies suggest that deletion of ROCK1 in bone marrow-derived cells is atheroprotective. However, the role for ROCK2 in the pathogenesis of atherosclerosis has not been determined. In the present article, we show that ROCK2-deficient mice on a genetic atherosclerotic background developed substantially fewer atherosclerotic lesions in the aorta and subaortic sinus after consumption of a high-cholesterol diet. These findings correlated with decreased foam cell formation and increased cholesterol efflux in ROCK2-deficient mice that are mediated, in part, through the peroxisome proliferator-activated receptor-γ/liver X receptor/ATP-binding cassette transporter A1 pathway in macrophages. In contrast, cholesterol efflux was unchanged in ROCK1-deficient macrophages, indicating a distinct role for ROCK2 in the reverse cholesterol transport system. These findings provide important and novel insights into the signaling mechanism that governs cholesterol efflux, which could lead to the development of selective ROCK inhibitors as therapeutic agents for atherosclerotic vascular disease.
Conclusions-ROCK2 contributes to atherosclerosis, in part, by inhibiting peroxisome proliferator-activated receptor-γ-mediated reverse cholesterol transport in macrophages, which contributes to foam cell formation. These findings suggest that inhibition of ROCK2 in macrophages may have therapeutic benefits in preventing the development of atherosclerosis. 8
Ca 2+ /Calmodulin-Dependent Protein Kinase II-Based Regulation of Voltage-Gated Na + Channel in Cardiac Disease
Summary-Defects in ion channel activity have been linked to increased susceptibility to cardiac arrhythmia in congenital and acquired forms of heart disease. Over the past 20 years, gene variants in ion channels have been discovered that increase arrhythmia susceptibility by altering ion channel biophysics. Although these studies have generated insight into molecular mechanisms underlying human disease and have advanced our understanding of ion channel function, the mechanistic link between specific molecular defects and arrhythmias remains elusive in many cases. Membrane protein posttranslational modifications are an essential mechanism for regulating cell function in heart. Importantly, alterations in posttranslational modification of ion channel proteins have now been identified in heart disease. Our findings demonstrate that human variants that modify a validated phosphorylation motif for Ca 2+ /calmodulin-dependent kinase in the cardiac sodium channel confer a proarrhythmic cellular phenotype by mimicking the Ca 2+ /calmodulin-dependent protein kinase II-phosphorylated channel. Moreover, we provide data that a similar defect in posttranslational modification of Na v 1.5 is present in a large-animal model of ischemic heart disease and human heart failure. We propose that the A572D and Q573E human arrhythmia variants belong to an emerging class of atypical ion channel mutations that confer arrhythmia susceptibility by affecting posttranslational modification. These studies add to mounting evidence that defects in local signaling and protein posttranslational modification help define disease phenotypes associated with a broad range of cardiac arrhythmia syndromes.
Conclusions-We identify the mechanism for 2 human arrhythmia variants that affect Na v 1.5 channel activity through direct effects on channel posttranslational modification. We propose that the Ca 2+ / calmodulin-dependent protein kinase II phosphorylation motif in the Na v 1.5 DI-DII cytoplasmic loop is a critical nodal point for proarrhythmic changes to Na v 1.5 in congenital and acquired cardiac disease. 9
G 13 -Mediated Signaling Pathway Is Required for Pressure Overload-Induced Cardiac Remodeling and Heart Failure
Summary-Cardiac remodeling in response to pressure or volume overload plays an important role in the pathogenesis of heart failure. Various mechanisms have been suggested to translate mechanical stress into structural changes, eg, the release of humoral factors such as angiotensin II and endothelin-1, which are believed to induce cardiac hypertrophy through activation of receptors coupled to the G q/11 family of heterotrimeric G proteins. Most G q/11 -coupled receptors, however, can also activate G proteins of the G 12/13 family, but the role of G 12/13 in cardiac remodeling is not understood. We show in this study that inducible, cardiomyocyte-specific inactivation of the α subunit of G 13 , Gα 13 , does not affect basal heart function but protects mice from pressure overload-induced hypertrophy and fibrosis as efficiently as inactivation of Gα q/11 . Furthermore, inactivation of Gα 13 prevents the development of heart failure up to 1 year after overloading. On the molecular level, we show that Gα 13 , but not Gα q/11 , controls agonist-induced expression of hypertrophy-specific genes through activation of the small GTPase RhoA and consecutive
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activation of myocardin-related transcription factors. Taken together, our results show that the signaling cascade Gα 13 -RhoA-myocardinrelated transcription factor regulates the expression of hypertrophic and fibrotic genes in cardiomyocytes. The finding that inactivation of Gα 13 prevents cardiac decompensation for up to 1 year after the onset of pressure overload makes this signaling pathway a promising target for therapeutic intervention in chronic heart failure.
Conclusions-Our data show that the G 12/13 family of heterotrimeric G proteins is centrally involved in pressure overload-induced cardiac remodeling and plays a central role in the transition to heart failure. 10
Dietary Nitrate Supplementation Improves Revascularization in Chronic Ischemia
Summary-With the worldwide increase in cardiovascular diseases in recent decades, the need for novel preventive and noninvasive therapeutic strategies has grown tremendously. In this context, there is accumulating evidence that inorganic nitrate from dietary sources is able to influence the hallmarks of cardiovascular functions, including blood pressure regulation. The bioactivation of nitrate from dietary or endogenous sources is carried out mainly by commensal bacteria that express effective nitrate reductase enzymes and are located in the gastrointestinal tract and on body surfaces. Under conditions of low oxygen tensions, nitrate and nitrite are physiologically recycled in blood and tissues to form nitric oxide and other bioactive nitrogen oxides that mediate cytoprotective signaling in the setting of pathological ischemia. The present study provides the first evidence that dietary nitrate supplementation improves revascularization in chronic ischemia. This study identified that dietary nitrate supplementation increases mobilization and migration of regenerative cells, improves the regenerative capacities of chronically ischemic tissue, and decreases apoptosis at the site of ischemia. Eradicating the commensal bacteria in the oral cavity and thus interrupting the bioactivation of the ingested nitrate decreased circulating levels of bioactive nitrogen oxides and reversed all of these beneficial effects. These data underscore the potential therapeutic value of inorganic nitrate and suggest the possible application of a nutritional approach in the prevention and treatment of cardiovascular diseases.
Conclusions-Long-term dietary nitrate supplementation may represent a novel nutrition-based strategy to enhance ischemia-induced revascularization. 11
Rapid Estrogen Receptor Signaling Is Essential for the Protective Effects of Estrogen Against Vascular Injury
Summary-Clinical studies have shown that estrogen therapy in postmenopausal women has the potential to exert both beneficial and harmful cardiovascular effects. Therefore, better understanding of the molecular mechanisms by which estrogen exerts its cardiovascular effects could lead to the development of new therapeutic agents that provide the beneficial effects of estrogen on the cardiovascular system without concomitant harmful effects. Estrogen signals through estrogen receptors (ERs) via 2 major signaling pathways: (1) a classic genomic pathway in which ERs directly regulate gene expression (genomic signaling) and (2) a rapid, nonnuclear pathway in which ERs activate specific kinase cascades at the cell membrane. In this article, we demonstrate that this rapid, nonnuclear signaling pathway is required for estrogen-mediated inhibition of vascular smooth muscle cell proliferation, both in vitro and in vivo. We show further that estrogen-mediated protection against vascular injury also requires rapid ER signaling in an in vivo mouse model. These findings support the concept that development of therapeutic agents that selectively activate rapid, nonnuclear ER signaling, without activating genomic signaling, may represent a novel therapeutic approach to prevent cardiovascular disease.
Conclusions-Taken together, these results support the concept that rapid, nonnuclear ER signaling contributes to the transcriptional regulatory functions of ER and is essential for many of the vasoprotective effects of estrogen. These findings also identify the rapid ER signaling pathway as a potential target for the development of novel therapeutic agents. 12
Conditional Targeting of Tumor Necrosis Factor Receptor-Associated Factor 6 Reveals Opposing Functions of Toll-Like Receptor Signaling in Endothelial and Myeloid Cells in a Mouse Model of Atherosclerosis
Summary-Atherosclerosis is the major cause of death in Westernized societies, being the underlying cause of severe cardiovascular diseases such as heart attack and stroke. Toll-like receptor (TLR) signaling has been implicated as a critical pathogenic factor in atherosclerosis and has attracted increased interest as a potential therapeutic target for the treatment of atherosclerosis. Our in vivo studies showed that TLR signaling exerts surprisingly diverse functions in endothelial cells and macrophages differentially affecting the development of atherosclerosis. Endothelial cell-specific inhibition of TLR signaling reduced atherosclerosis severity in female mice by inhibiting nuclear factor-κB activation and the expression of proinflammatory mediators by the vascular endothelium in response to oxidized lipids, resulting in less efficient recruitment of monocytes into the developing plaques. In contrast, myeloid cell-specific inhibition of TLR signaling surprisingly resulted in more severe atherosclerosis by compromising the antiinflammatory properties, endoplasmic reticulum stress survival responses, and efferocytosis capacity of macrophages. Collectively, these results revealed a previously unappreciated functional diversity of TLR signaling in 2 cell types that are critical for the development of atherosclerosis. In response to modified lipids, TLR signaling exerts proatherogenic functions in endothelial cells in female mice by inducing the expression of proinflammatory mediators facilitating monocyte recruitment. In contrast, TLR signaling in macrophages is atheroprotective by inducing interleukin-10 expression, suppressing endoplasmic reticulum stress-induced macrophage death, and stimulating efferocytosis. These findings urge caution in the systemic application of TLR signaling inhibitors in atherosclerosis and suggest that strategies specifically targeting endothelial cells would have a greater therapeutic potential.
Conclusions-Toll-like receptor-mediated tumor necrosis factor receptor-associated factor 6 (TRAF6) signaling acts in endothelial cells to promote atherosclerosis but displays atheroprotective, antiinflammatory and prosurvival functions in myeloid cells. 13
Myocardial Relaxation, Restoring Forces, and Early-Diastolic Load Are Independent Determinants of Left Ventricular Untwisting Rate
Summary-Measurement of the left ventricular (LV) untwisting rate (UTR) by speckle tracking echocardiography represents a means to evaluate diastolic function, and UTR has been proposed as a marker of the rate of LV relaxation. The present experimental study confirmed the relationship between peak UTR and rate of LV relaxation. In addition, restoring forces generated by systolic contraction, analogous to the elastic recoil after release of a compressed spring, was another important independent determinant of peak UTR.
Furthermore, the present study indicated that early-diastolic load, measured as LV pressure at the onset of filling, is an important and independent determinant of peak UTR. Therefore, in the assessment of LV relaxation rate by measurement of peak UTR, one needs to take into account LV diastolic pressure and the magnitude of restoring forces, as well. Clinically, early-diastolic load would approximate LV end-diastolic pressure, and restoring forces may be reflected in end-systolic volume. The demonstration that restoring forces and early-diastolic load are independent determinants of peak untwisting rate, in addition to the rate of relaxation, may have an impact on how measurements of untwisting rate are interpreted in a clinical context. LV untwisting occurs during LV relaxation and early filling and is therefore a feature of diastole. However, because restoring forces are generated by systolic contraction, changes in peak UTR may also be attributed to changes in contractility. Therefore, it may not be appropriate to conclude that a change in peak UTR reflects a true change in diastolic function.
Conclusions-
The present study indicates that early-diastolic load, restoring forces, and relaxation rate are independent determinants of peak UTR. However, only relaxation rate and restoring forces contributed to UTR during isovolumic relaxation. 14
Targeting Mannose-Binding Lectin Confers Long-Lasting Protection With a Surprisingly Wide Therapeutic Window in Cerebral Ischemia
Summary-Despite recent substantial progress in prevention and supportive care, stroke is still a leading cause of death and permanent disability worldwide. To date, thrombolysis with tissue plasminogen activator is the only available treatment and its narrow therapeutic window (3-4.5 hours) is one of the main obstacles to finding eligible patients. Thus, new approaches with a wider window of efficacy are needed. This study documents the pivotal role of mannose-binding lectin (MBL), a circulating protein that acts as the first step in activation of the lectin complement pathway in brain ischemic injury. The data show that MBL deposition on the ischemic endothelium represents a key pathogenetic event in brain damage. Importantly, strategies aimed at inhibiting MBL lead to neuroprotection with a time window of efficacy up to 24 to 30 hours postinjury, an extremely important factor in the attempt to translate experimental results into the clinical setting. Detailed analysis of the MBL gene in humans has revealed that a surprisingly high percentage of individuals (15%-30% depending on the population considered) carries a genetic deficiency in MBL that leads to low circulating levels of MBL. Notably, this deficiency is associated with a better outcome after acute stroke in humans. Our data, providing a mechanistic insight into the role of MBL in brain ischemia and the demonstration that its inhibition is protective, strongly support the concept of MBL as a relevant therapeutic target in humans, one with a wide therapeutic window of application. Thus, we propose MBL as a novel therapeutic target for stroke.
Conclusions-Our data show an important role for MBL in the pathogenesis of brain ischemic injury and provide a strong support to the concept that MBL inhibition may be a relevant therapeutic target in humans, one with a wide therapeutic window of application. 15
Dissociation of Structural and Functional Phenotypes in Cardiac Myosin-Binding Protein C Conditional Knockout Mice
Summary-Mutations in the gene encoding cardiac myosin-binding protein-C (cMyBP-C) are common causes of familial hypertrophic cardiomyopathy (HCM) and can also lead to HCM-associated dilation. This primary disease of the myocardium affects a wide range of patient age groups, accounts for the majority of cardiac genetic diseases, and leads to significant morbidity and mortality associated with the development of heart failure, ventricular and atrial arrhythmias, myocardial infarction, and sudden cardiac death. Nevertheless, little is known regarding the mechanisms underlying the development of cMyBP-C-associated HCM, although deficiencies in cMyBP-C are thought to contribute to the pathogenesis of this disease in many cases. Herein, we investigate the onset, progression, and saturation of structural and functional phenotypes caused by the removal of cMyBP-C and assess whether loss of cMyBP-C per se is sufficient to cause the development of HCM-associated dilation.
Using adult cMyBP-C conditional knockout mice, we show that acute loss of cMyBP-C affects the duration of cardiac systole and diastole and contributes to the development of diastolic dysfunction, all of which occurs before the onset of cardiac hypertrophy. Moreover, we show that near-complete ablation of cMyBP-C is insufficient to cause HCM-associated dilation in adult mice, whereas the imposition of additional stresses such as increased afterload is sufficient to recapitulate the phenotype. These results help define the gradual changes that precede and progress with the clinical expression of cMyBP-C-associated cardiomyopathy and identify potential avenues in which to prevent, delay, or reverse the progression of this disease.
Conclusions-These results indicate that myocardial dysfunction is largely caused by the removal of cMyBP-C and occurs before the onset of cytoarchitectural remodeling in tamoxifen-treated cMyBP-C-cKO myocardium. Moreover, near ablation of cMyBP-C in adult myocardium primarily leads to the development of hypertrophic cardiomyopathy in contrast to the dilated phenotype evident in cMyBP-C −/− mice, which highlights the importance of additional factors such as loading stress in determining the expression and progression of cMyBP-C-associated cardiomyopathy. 16
Endothelium-Selective Activation of AMP-Activated Protein Kinase Prevents Diabetes Mellitus-Induced Impairment in Vascular Function and Reendothelialization via Induction of Heme Oxygenase-1 in Mice
Summary-Diabetes mellitus is closely associated with accelerated atherosclerosis and an increased risk of cardiovascular disease. Endothelial dysfunction, which is caused in part by impaired endothelium-reparative capacity of endothelial progenitor cells (EPCs), is an early event in diabetes mellitus and in the pathogenesis of atherosclerosis. Therefore, therapeutic interventions targeting endothelial dysfunction hold great promise for the treatment of cardiovascular complications in diabetic patients. Emerging evidence from animal and clinical studies suggests that AMP-activated protein kinase (AMPK), a master regulator of energy homeostasis, exhibits pleiotropic beneficial effects on both endothelial cells and EPCs. A number of drugs with antidiabetic or cardiovascular protective properties, including metformin, statins, thiazolidinediones, fenofibrate, and estradiol, have been shown to activate AMPK in endothelial cells or EPCs. However, because of the ubiquitous expression pattern of AMPK, it is currently unclear whether the protective effects of these agents against endothelial dysfunction are a direct consequence of AMPK activation in endothelial cells or EPCs or an indirect effect related to the improvement in insulin sensitivity and glycemic control. In the present study, we generated a transgenic mouse model with selective activation of AMPK in both endothelial cells and EPCs and demonstrated that these transgenic mice are resistant to diabetes mellitus-induced impairment in endothelial function and reparative
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neovascularization. Furthermore, we showed that endothelial AMPK promotes reendothelialization of injured blood vessels by activation of heme oxygenase-1, another potential therapeutic target for cardiovascular disease. These findings suggest that selective therapeutic activation of AMPK in endothelial cells or EPCs is sufficient to prevent the vascular complications of diabetes mellitus.
Conclusions-Endothelium-specific AMPK activation is sufficient to protect against diabetes mellitus-induced aggravation of vascular injury by promoting EPC function and reendothelialization via upregulation of heme oxygenase-1 and stromal cell derived facotor-1α. 17
Loss of Perivascular Adipose Tissue on Peroxisome Proliferator-Activated Receptor-γ Deletion in Smooth Muscle Cells Impairs Intravascular Thermoregulation and Enhances Atherosclerosis
Summary-Recent confirmation that in addition to white adipose tissue, brown adipose tissue (BAT) is found in adult humans, where it plays a distinct role in adaptive thermoregulation and energy metabolism, has sparked active research on adipose tissues as bioactive organs, mostly focusing on their pathophysiological aspects for treatment of metabolic disorders. This revival led to the recognition of perivascular adipose tissue (PVAT) not just as a support structure but rather as a biologically active regulatory component of the vasculature. Despite increased understanding of PVAT autocrine and paracrine vascular roles, there is a paucity of knowledge regarding its involvement in atherosclerosis. PVAT shares some characteristics with BAT, but to date, its specific roles remain obscure because of limited animal models. We present experimental proteomics evidence that in vivo chronic cold stimulus results in activation of PVAT characterized by cellular metabolic pathways shared with BAT. A peroxisome proliferator-activated receptor-γ-knockout strategy targeting smooth muscle cells results in loss of PVAT surrounding the vasculature. Use of this unique model in combination with our newly developed surgical removal of BAT reveals, for the first time, robust atheroprotection mediated by adaptive thermogenic activation of PVAT in chronic cold adaptation associated with a reduction of plasma lipid profiles and improvement of the endothelial dysfunction. Endothelial protective effects likely result from increased prostacyclin release by activated PVAT. Thus, we uncovered a new paradigm that directly links PVAT to the beneficial effects of cold exposure and thermogenesis in atherosclerosis likely to mimic those observed in humans.
Conclusions-PVAT is a vasoactive organ with functional characteristics similar to BAT and is essential for intravascular thermoregulation of cold acclimation. This thermogenic capacity of PVAT plays an important protective role in the pathogenesis of atherosclerosis. 18
Activity of the Estrogen-Metabolizing Enzyme Cytochrome P450 1B1 Influences the Development of Pulmonary Arterial Hypertension
Summary-Pulmonary arterial hypertension (PAH) is a fatal condition with diverse origins that converge to promote pathological changes in the pulmonary vasculature. The nature of these origins is intriguing and stems from genetic and environmental factors to secondary risk factor-related disease. Estrogen is one such risk factor that has been causally related to PAH; however, the causation remains obscure. In this study, we have identified that the estrogen-metabolizing enzyme cytochrome P450 1B1 (CYP1B1) controls the formation of estrogen-derived mitogenic metabolites to drive vascular cell mitogenesis and PAH. Central to this, we report that CYP1B1 is robustly upregulated in 2 independent forms of clinical PAH, whereas the inhibition of this enzyme markedly inhibits the proliferative capacity of pulmonary artery smooth muscle cells isolated from PAH patients. In vivo, CYP1B1 is upregulated in 2 independent models of PAH, whereas the genetic ablation or pharmacological inhibition of CYP1B1 markedly attenuates the development of PAH, as reported in CYP1B1 −/− and 2,3′,4,5′-tetramethoxystilbene-treated mice, respectively. Further investigation of estrogen metabolites reveals that 16α-hydroxyestrone is a key metabolite that robustly stimulates smooth muscle mitogenesis and promotes the development of PAH in mice in vivo. This study reinforces a pathogenic role of estrogen in human PAH and reveals for the first time the importance of estrogen metabolism in the genesis and progression of PAH.
Conclusions-Increased CYP1B1-mediated estrogen metabolism promotes the development of PAH, likely via the formation of mitogens, including 16α-hydroxyestrone. Collectively, this study reveals a possible novel therapeutic target in clinical PAH. 19
Impaired Natural Killer Cell Phenotype and Function in Idiopathic and Heritable Pulmonary Arterial Hypertension
Summary-Pulmonary arterial hypertension (PAH) is a disease of occlusive vascular remodeling that leads to elevated pulmonary arterial pressure and death from right heart failure. An association between PAH and immune dysfunction has been recognized for decades, although the cellular basis for this link has remained obscure.
In the current study, we identify a defect in the circulating natural killer (NK) cells of PAH patients and 2 widely used animal models of disease. Beyond their traditional function as the cytotoxic effector cells of innate immunity, several studies have recently demonstrated a role for NK cells in the regulation of spiral artery remodeling during pregnancy, tumor angiogenesis and the revascularization of ischemic limbs. By drawing upon recent literature characterizing the impairment of NK cells in HIV infection, we identify an altered NK cell phenotype in PAH patients that is exemplified by decreased surface expression of certain killer immunoglobulin-like receptors, diminished cytotoxicity, reduced cytokine secretion, and the increased production of matrix-degrading enzymes, including matrix metalloproteinase 9. We also propose a mechanism whereby this NK cell impairment is the result of excessive transforming growth factor-β signaling. Our work is the first to propose a direct role for NK cells in the regulation of pulmonary vascular remodeling. This discovery, which is based on emerging concepts from reproductive medicine and immunology, not only highlights the importance of cellular immunity in the pathobiology of PAH, but also provides a potential therapeutic target for the design of new PAH treatments.
Conclusions-Our work is the first to identify an impairment of NK cells in PAH and suggests a novel and substantive role for innate immunity in the pathobiology of this disease. 20 research by virtue of their ability to sense danger in response to hypercholesterolemia, tissue stress, or necrosis, and drive macrophage activation and inflammation in the vessel wall. TLR2 and TLR4, in particular, have been shown to play a critical role in promoting plaque development and vulnerability leading to the view that all TLRs are pathogenic for this disease. This article now reports the surprising finding that TLR7, an endosomal TLR that recognizes viral single-stranded RNA and self-RNA released from necrotic cells, is protective. In experimental atherosclerosis in mice, TLR7 prevented lesion development, stenosis, and plaque vulnerability by constraining monocyte chemoattractant protein-1 production, Ly6C hi "inflammatory" monocyte expansion and M1 inflammatory macrophage accumulation to developing atherosclerotic lesions. In human carotid endarterectomy specimens, TLR7 was positively associated with an M2 anti-inflammatory macrophage signature and collagen genes and inversely related/unrelated to proinflammatory mediators and platelet markers, whereas TLR7 activation in human atheroma cultures selectively suppressed the production of monocyte chemoattractant protein-1. Altogether, these findings reveal that TLR7 is part of a protective response that limits atherosclerotic plaque development and vulnerability and challenge the prevailing concept that all TLRs are pathogenic. They also provide new insight about the complex interplay of innate immunity in atherosclerosis and support the exploitation of the TLR7 pathway for therapy.
Toll-Like Receptor 7 Protects From Atherosclerosis by Constraining "Inflammatory" Macrophage Activation
Conclusions-These findings provide evidence for a beneficial role of TLR7 in atherosclerosis by constraining inflammatory macrophage activation and cytokine production. This challenges the prevailing concept that all TLRs are pathogenic and supports the exploitation of the TLR7 pathway for therapy. 21
MicroRNA-101 Inhibited Postinfarct Cardiac Fibrosis and Improved Left Ventricular Compliance via the FBJ Osteosarcoma Oncogene/Transforming Growth Factor-β1 Pathway
Summary-Myocardial infarction caused by coronary artery occlusion is one of the leading causes of sudden death in the world. Interstitial fibrosis, occurring in both infarcted and noninfarcted myocardium, represents a characteristic pathological alteration of postinfarct remodeling and is regarded as a major determinant of the progressive deterioration of ventricular function and reduced ventricular compliance after myocardial infarction. Fibrosis is characterized by excessive deposition of extracellular matrix proteins. Cardiac fibroblasts, accounting for 60% to 70% of the cells in the human heart, are the main source of extracellular matrix protein production. During myocardial infarction, cardiac fibroblasts are activated and produce excessive amount of extracellular matrix proteins, leading to interstitial fibrosis. Tremendous efforts have been devoted to this pathological process to elucidate the molecular mechanisms and to develop novel antifibrotic strategies. MicroRNAs (miRs), endogenous small noncoding RNAs that regulate the expression of genes, have recently been proven to be a novel class of regulators of cardiovascular diseases, including those associated with cardiac fibrosis.
In this study, we discovered that downregulation of an miR called miR-101 contributes significantly to cardiac fibrosis in myocardial infarction hearts; forced expression of miR-101 suppresses cardiac fibrosis and improves the impaired cardiac function in postinfarct rats. Our findings reveal the role of miRNA in controlling cardiac fibrosis in myocardial infarction hearts and indicate that miR-101 is a viable therapeutic strategy for cardiac disease associated with fibrosis. It is speculated that administration of miR-101 mimetics should produce antifibrotic actions, thereby retarding structural remodeling and minimizing functional deterioration of the heart under a variety of pathological settings.
Conclusions-Overexpression of miR-101a can mitigate interstitial fibrosis and the deterioration of cardiac performance in postinfarct rats, indicating the therapeutic potential of miR-101a for cardiac disease associated with fibrosis. 22
High Levels of Circulating Epinephrine Trigger Apical Cardiodepression in a β 2 -Adrenergic Receptor/G i -Dependent Manner: A New Model of Takotsubo Cardiomyopathy
Summary-Takotsubo cardiomyopathy is an increasingly recognized clinical syndrome characterized by severe acute (but reversible) apical ventricular dysfunction, ST elevation, and unobstructed coronary arteries. Physical or emotional stress is a frequent precipitant, as well as iatrogenic catecholamine exposure. We generated a model of Takotsubo cardiomyopathy using a single high bolus dose of epinephrine in anesthetized rats, which reproduced the reversible apical hypocontractility. We explored the subcellular mechanisms and identified that high-dose epinephrine activated a switch of β 2 -adrenergic receptor (β 2 AR) coupling from the positively inotropic G s -cAMP to a negatively inotropic G i signaling pathway. Norepinephrine, which does not activate this G s /G i switch, did not precipitate apical dysfunction. Proportionately higher β 2 AR numbers at the apex produced the apical-basal gradient in contractility. Prevention of the switch increased sudden death in this model, which is consistent with the protective antiarrhythmic and antiapoptotic nature of G i signaling. We screened various β-blockers (given after apical dysfunction was established) using the model and noted that propranolol, which also switches β 2 AR to the G i pathway, exacerbated contractile dysfunction without increasing mortality. Carvedilol had similar but less pronounced effects, and bisoprolol did not affect the response. Avoiding the βAR-cAMP axis with the calcium myofilament sensitizer levosimendan, we were able to completely rescue the acute Takotsubo syndrome, with 100% survival. This model suggests that an epinephrine-induced β 2 AR G s /G i switch is responsible for the acute apical dysfunction in Takotsubo cardiomyopathy but that it may also confer an element of protection against damage by high catecholamines.
Conclusions-We suggest that biased agonism of epinephrine for β 2 AR-G s at low concentrations and for G i at high concentrations underpins the acute apical cardiodepression observed in Takotsubo cardiomyopathy, with an apical-basal gradient in β 2 ARs explaining the differential regional responses. We suggest this epinephrinespecific β 2 AR-G i signaling may have evolved as a cardioprotective strategy to limit catecholamine-induced myocardial toxicity during acute stress. 23
Noninvasive Magnetic Resonance Imaging Evaluation of Endothelial Permeability in Murine Atherosclerosis Using an Albumin-Binding Contrast Agent
Summary-Despite the systemic and multifactorial nature of atherosclerosis, lesion development is focal and occurs at particular regions of the vasculature including the branches, the inner curvature, and the outer wall of bifurcations, where focal hemodynamic factors exert major damage on the vascular endothelium. Although several imaging modalities are now available for imaging of atherosclerosis, most of the work has focused on identifying anatomic changes associated
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with disease progression and risk, which have shown low predictive value. Conversely, the combination of imaging structural and functional properties of the vessel wall may allow investigation of the manner in which the extent of local artery disease is related to the degree of local abnormal endothelial function. Therefore, noninvasive physiological imaging of endothelial permeability and function may offer a comprehensive methodology for monitoring focal atherosclerotic progression in both early and later stages, as well as plaque instability, and testing the effectiveness of treatment interventions targeting vascular endothelium integrity and function.
Conclusions-We demonstrate the noninvasive assessment of endothelial permeability and function with the use of an albumin-binding magnetic resonance contrast agent. Blood albumin leakage could be a surrogate marker for the in vivo evaluation of interventions that aim to restore the endothelium. 24
Cyclin-Dependent Kinase 5-Mediated Hyperphosphorylation of Sirtuin-1 Contributes to the Development of Endothelial Senescence and Atherosclerosis
Summary-Aging is a major risk factor for cardiovascular diseases. Endothelial senescence represents one of the early aging characteristics during the development of atherosclerosis in human arteries. SIRT1 is an enzyme responsible for deacetylating a diverse range of protein targets. The role of its yeast homolog, Sir2p, in lifespan extension was reported in the late 1990s. Since then, a vast amount of information has supported the potential antiaging activity of SIRT1 in rodents and humans. This study identified an important posttranslational modification (S47 phosphorylation) of SIRT1 that was augmented during endothelial senescence. By inhibition of the upstream kinase (cyclin-dependent kinase 5), the development of atherosclerosis and vascular inflammation in mice was significantly halted. This evidence demonstrates that SIRT1 is an antivascular aging factor and that it may be a promising therapeutic target for cardiovascular diseases.
Conclusions-Cyclin-dependent kinase 5-mediated hyperphosphorylation of SIRT1 facilitates the development of endothelial senescence and atherosclerosis. 25
Ca 2+ -Stimulated Adenylyl Cyclase AC1 Generates Efficient Biological Pacing as Single Gene Therapy and in Combination With HCN2
Summary-In the United States, ≈300 000 pacemakers are implanted annually, 5% of which result in serious complications requiring surgical revision or other invasive procedures. In addition, electronic pacemakers have limitations such as an inadequate autonomic response, limited battery life, and restrictions with regard to stable lead positioning. These issues may be dealt with in part by the development of biological pacemakers. Within the framework of biological pacing, the AC1-based approach shows potential because it generates highly stable pacemaker function at beating rates of ≈60 bpm and incorporates sensitivity to sympathetic and parasympathetic input. Two important hurdles on the road to clinical application include the demonstration of stable long-term function and the demonstration of safety with regard to both potential proarrhythmia and toxicity. The continued development of electronic pacemakers may obviate the need for biological alternatives, but regardless of whether biological pacemakers find clinical application, their development will continue to increase our understanding of pacemaker function and of cardiac gene therapy.
Conclusions-AC1 or HCN2/AC1 overexpression in left bundle branches provides highly efficient biological pacing and greater sensitivity to autonomic modulation than HCN2 alone. 26
Interleukin-10 Treatment Attenuates Pressure Overload-Induced Hypertrophic Remodeling and Improves Heart Function via Signal Transducers and Activators of Transcription 3-Dependent Inhibition of Nuclear Factor-κB
Summary-Chronic stress-induced hypertrophic growth of the myocardium leads to an increased risk of cardiovascular events, heart failure, and death. Experimental evidence suggests a potential role of inflammation in the progression of heart failure; however, the mechanisms of this process are not fully understood. The present study elucidates the novel therapeutic efficacy of the antiinflammatory cytokine interleukin-10 (IL-10) in both the prevention and attenuation of pathological hypertrophy and heart failure in 2 models of pressure overload. Additionally, our study provides the mechanism through which IL-10 imparts its therapeutic benefits for cardioprotection. The significance of the protective effect of IL-10 is further supported by an exaggerated adverse remodeling after pressure overload in IL-10 knockout mice. Importantly, we show that pretreatment of mice with exogenous recombinant IL-10 before either isoproterenol-or transverse aortic constriction-induced hypertrophic stimulus prevents ventricular remodeling, excessive fibrosis, and cardiomyocyte death and preserves left ventricular functions. Moreover, IL-10 treatment, once hypertrophy has been established, also attenuates adverse remodeling and fibrosis in animals with pressure overload. These findings that IL-10 therapy prevents cardiac remodeling and preserves cardiac function in the face of pressure overload stress have significant bearing not only on our understanding of the mechanisms involved in IL-10 action but also on the potential future clinical and therapeutic use of IL-10 and/or its downstream signaling components for the treatment of heart failure. Thus, IL-10 treatment may be a novel therapeutic approach to prevent and cure the hypertrophic cardiac remodeling in patients.
Conclusions-Taken together, our results suggest IL-10 treatment as a potential therapeutic approach to limit the progression of pressure overload-induced adverse cardiac remodeling. 27
Transplantation and Tracking of Human-Induced Pluripotent Stem Cells in a Pig Model of Myocardial Infarction: Assessment of Cell Survival, Engraftment, and Distribution by Hybrid Single Photon Emission Computed Tomography/Computed Tomography of Sodium Iodide Symporter Transgene Expression
Summary-Cardiac cell replacement therapies may significantly extend current therapeutic options for various cardiac diseases. The recently developed induced pluripotent stem cells are considered a major breakthrough with respect to the development of novel regenerative therapies and combine the advantages of adult and embryonic stem cells, namely, the availability of an autologous, ethically nonproblematic cell source with high potential for proliferation and differentiation into all cell lineages of interest. However, evaluation of novel cellular therapies in preclinical large-animal models and patients is currently hampered by the lack of suitable imaging approaches that allow long-term monitoring of viable transplanted cells. The present study was therefore designed to evaluate sodium iodide symporter e354 Circulation October 22, 2013 transgene imaging as a novel approach to follow human induced pluripotent stem cell derivatives in a pig model of myocardial infarction. For the first time, our study demonstrates the usefulness of a sodium iodide symporter transgene for longitudinal in vivo tracking of survival, engraftment, and distribution of cellular grafts in a large-animal model with the use of single photon emission tomographic/computed tomographic imaging. Moreover, for the first time we demonstrate long-term survival and differentiation of human induced pluripotent stem cells in a preclinical pig model of myocardial infarction. The applied 3-dimensional hybrid imaging protocol enables combined assessment of cardiac anatomy and myocardial perfusion and monitoring of donor cell survival, proliferation, and distribution within 1 imaging modality. The developed approach will contribute to further optimization of novel cardiovascular cell-based treatment strategies and is of utmost importance for careful in vivo monitoring of associated risks such as potential tumor or teratoma formation.
Conclusions-This study describes for the first time the feasibility of repeated long-term in vivo imaging of viability and tissue distribution of cellular grafts in large animals. Moreover, this is the first report demonstrating vascular differentiation and long-term engraftment of hiPSCs in a large-animal model of myocardial infarction. NIS pos -hiPSCs represent a valuable tool to monitor and improve current cellular treatment strategies in clinically relevant animal models. 28
Histone Deacetylation Inhibition in Pulmonary Hypertension: Therapeutic Potential of Valproic Acid and Suberoylanilide Hydroxamic Acid
Summary-Histone deacetylases (HDACs) have emerged as key targets to reverse aberrant epigenetic changes associated with cancer and autoimmune disease, and HDAC inhibitors show promise as anticancer and antiinflammatory agents. We examined the pattern of HDAC expression in lungs from patients with pulmonary arterial hypertension and investigated the effect of HDAC inhibition on the reversal of pulmonary hypertension in a rat model. Coupled to this, we explored the effects on mechanisms (proliferation, apoptosis, and inflammation) relevant to the pathology of pulmonary arterial hypertension in human and animal cell model systems. Our results demonstrate that increased HDAC activity contributes to the vascular pathology of pulmonary hypertension. The effectiveness of the HDAC inhibitors valproic acid and suberoylanilide hydroxamic acid in models of pulmonary arterial hypertension supports a therapeutic strategy based on HDAC inhibition in pulmonary arterial hypertension.
Conclusions-Increased HDAC activity contributes to the vascular pathology of pulmonary hypertension. The effectiveness of HDAC inhibitors, valproic acid, and suberoylanilide hydroxamic acid, in models of pulmonary arterial hypertension supports a therapeutic strategy based on HDAC inhibition in pulmonary arterial hypertension. 29
Nucleotide Excision DNA Repair Is Associated With Age-Related Vascular Dysfunction
Summary-Aging strongly contributes to cardiovascular disease. It prolongs exposure to classic cardiovascular risk factors such as hypertension and diabetes mellitus but also acts as an independent risk factor. Recent evidence suggests that gradually accumulating DNA damage, leading to genomic instability, is a main cause of aging. This study is the first to show that mice with a defective DNA repair system not only age fast but also display accelerated development of vascular problems mimicking those in aging humans: increased blood pressure, increased vascular stiffness, decreased vascular relaxation, and cellular aging. Of interest, phosphodiesterase inhibition acutely improved the diminished relaxation in vitro, suggesting that enhanced breakdown of cGMP may underlie this phenomenon. Furthermore, in humans, variations in DNA repair genes were associated with markers for vascular aging. Taken together, these results indicate that genomic instability plays a central role in vascular aging. Genomic instability may also explain the high prevalence of cardiovascular death in Hutchinson-Gilford progeria and Werner progeroid syndrome, both of which feature genomic instability. Because oxidative stress is an important inductor of DNA damage, future agingsuppressor agents may involve drugs that improve genomic integrity (eg, statins and rapamycin) and drugs that prevent oxidative stress (eg, renin-angiotensin system blockers and antioxidants). In addition, drugs facilitating the nitric oxide-soluble guanylate cyclase-cGMPphosphodiesterase pathway might be of value. The successful application of such treatments requires proper risk stratification, preferably at younger ages. This might include analyses of genetic variations in DNA repair genes and the identification of all possible sources of cardiovascular DNA damage.
Conclusions-Mice with genomic instability recapitulate agedependent vascular dysfunction as observed in animal models and in humans but with an accelerated progression compared with wildtype mice. In addition, we found associations between variations in human DNA repair genes and markers for vascular stiffness, which is associated with aging. Our study supports the concept that genomic instability contributes importantly to the development of cardiovascular disease. 30
Lack of Microsomal Prostaglandin E 2 Synthase-1 in Bone Marrow-Derived Myeloid Cells Impairs Left Ventricular Function and Increases Mortality After Acute Myocardial Infarction
Summary-Millions of patients use nonsteroidal anti-inflammatory drugs (NSAIDS) to treat pain and inflammatory disorders. NSAIDS block the activity of cyclooxygenase-2 (COX-2), an enzyme that catalyzes the second of three steps in prostaglandin biosynthesis. Unfortunately, some COX-2 inhibitors are associated with an increased risk of myocardial infarction (MI) and stroke, possibly because of decreased production of antithrombotic eicosanoids, such as PGI 2 , combined with simultaneous unopposed production of prothrombotic thromboxane A 2 , an eicosanoid catalyzed via COX-1 in platelets. Microsomal prostaglandin E 2 synthase-1 (mPGES-1) is downstream from COX-2 in the inducible PGE 2 biosynthetic pathway. Inhibition or deletion of mPGES-1 decreases pain, fever and inflammation without increasing the propensity for thrombosis. Therefore, pharmacologic inhibitors of mPGES-1 may be a viable replacement for COX-2 inhibitors, and may not be associated with an increased risk of thrombotic cardiovascular events. We show that targeted deletion of mPGES-1 in bone marrow derived leukocytes that are recruited to the heart leads to left ventricular (LV) dilation, impaired LV systolic and diastolic function, adverse LV remodelling, and increased mortality after MI. These finding increase our understanding of the molecular events that control LV remodeling after MI, and demonstrate the importance of eicosanoid biosynthesis by inflammatory leukocytes in this process. However, caution is warranted in extrapolating the results of targeted deletion of mPGES-1 in bone marrow derived leukocytes in mice to the possible outcome of pharmacologic inhibition of mPGES-1 in clinical practice. Further studies, of mice and humans, are warranted to define the role of mPGES-1 in LV remodeling after MI.
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Conclusions-Lack of mPGES-1 in bone marrow-derived leukocytes negatively regulates COX-1 expression, prostaglandin E 2 biosynthesis, and inflammation in the infarct and leads to impaired LV function, adverse LV remodeling, and decreased survival after acute myocardial infarction. 31
Dietary Nitrate Ameliorates Pulmonary Hypertension: Cytoprotective Role for Endothelial Nitric Oxide Synthase and Xanthine Oxidoreductase
Summary-Loss of nitric oxide (NO) bioactivity underpins many of the hemodynamic and morphological changes in the cardiopulmonary circulation that characterize pulmonary hypertension, particularly the pulmonary arterial hypertension subclass. Recent evidence suggests that the NO metabolites nitrite (NO 2 − ) and nitrate (NO 3 − ) can be chemically reduced in vivo to biologically active NO, a phenomenon that occurs optimally under conditions of hypoxia and acidosis. This nitrate-nitrite-NO pathway has been shown to exert a number of beneficial effects, including lowering of systemic blood pressure and protection against ischemia-reperfusion injury. Herein, we have used 2 etiologically distinct experimental models of pulmonary hypertension to demonstrate that dietary nitrate (and, to a lesser extent, nitrite) can prevent and reverse the pathogenesis of this debilitating disease. In addition, we have identified the principal enzymatic routes (ie, endothelial NO synthase and xanthine oxidoreductase) by which endogenous NO generation occurs. These data provide convincing evidence that supplementation of dietary nitrate is likely to represent a novel means by which to slow, halt, or actually reverse the development of pulmonary hypertension. Exploitation of this mechanism represents a viable, orally active therapy for pulmonary hypertension that warrants evaluation in this patient population and, if efficacious, could be implemented rapidly and cost-effectively.
Conclusions-These data demonstrate that dietary nitrate, and to a lesser extent dietary nitrite, elicit pulmonary dilatation, prevent pulmonary vascular remodeling, and reduce the right ventricular hypertrophy characteristic of PH. This favorable pharmacodynamic profile depends on endothelial NO synthase and xanthine oxidoreductase -catalyzed reduction of nitrite to NO. Exploitation of this mechanism (ie, dietary nitrate/nitrite supplementation) represents a viable, orally active therapy for PH. 32
Targeted Deletion of MicroRNA-22 Promotes Stress-Induced Cardiac Dilation and Contractile Dysfunction
Summary-The identification of genes and pathways involved in progression to heart disease is a major challenge and focus in cardiac research. New evidence has established the importance of microRNAs (miRNAs) in controlling cardiac pathophysiology. The relevance of miR-22 to human heart failure has been suggested by the recent demonstration that miR-22 expression was either downregulated or upregulated in human dilated cardiomyopathy and diseased hearts. In the present report, we demonstrate that genetic ablation of the non-protein-coding gene miR-22 in mice impairs cardiac reserve to β-adrenergic stimulation with dobutamine. Here, we show that the absence of miR-22 increases vulnerability to pressure-overload-induced cardiac decompensation characterized by left ventricular dilation and loss of contractile function.The inability of mutant mice to adapt to biomechanical stress was caused in part by restrained expression of genes such as sarcoplasmic reticulum calcium ATPase (Serca2a), LIM domain binding 3 (Ldb3), cardiac LIM protein (Csrp3/Mlp), and Titin encoding calcium handling and other contractile/myofibrillar proteins implicated in human dilated cardiomyopathy. This phenotype was attributed in part to inappropriate inhibition of serum response factor-dependent gene expression in mutant hearts. In addition, we demonstrated that miR-22 inhibits the expression of purine-rich element binding protein B, a transcription factor that opposes control of sarcomeric/cardiac expression by serum response factor. These results demonstrate the importance of miR-22 as a homeostatic keeper of cardiac gene expression and modulator of cardiac contractile reserve to acute and hemodynamic stress. These results are the first to demonstrate a novel disease mechanism of cardiac pathogenesis involving miR-22.
Conclusions-These data indicate that miR-22 functions as an integrator of Ca 2+ homeostasis and myofibrillar protein content during stress in the heart and shed light on the mechanisms that enhance propensity toward heart failure. 33
Right or Left Ventricular Pacing in Young Minipigs With Chronic Atrioventricular Block: Long-Term In Vivo Cardiac Performance, Morphology, Electrophysiology, and Cellular Biology
Summary-In inborn or acquired atrioventricular block in small children, pacemaker electrodes traditionally were implanted into or sutured onto the right ventricle. This was suspected to cause dyssynchrony and heart failure. To determine optimal pacing electrode position, we performed a prospective study in minipigs with induced atrioventricular block comparing the effects of right ventricular free wall or left ventricular (LV) apex pacing (120 bpm) on LV hemodynamics, ultrastructure, and molecular remodeling. Right ventricular free wall pacing led to dyssynchrony and to more pronounced alterations in LV performance than LV apex pacing, whereas changes in calcium handling proteins, plasma catecholamines, and ultrastructure were unrelated to the location of ventricular pacing. LV stroke work, dP/dtmax, and dP/dtmin were reduced only in right ventricular free wall pacing. These data underline the importance of dyssynchrony for the development of LV dysfunction. Moreover, this study suggests LV apex pacing as the more suitable (better) pacing location and that avoidance of dyssynchrony is important in pacemaker implantation.
Conclusions-
The observed molecular remodeling seemed to be more dependent on heart rate than on dyssynchrony. LV apical pacing is associated with less dyssynchrony, a more physiological LV contraction pattern, and preserved LV function as opposed to RV free wall pacing. 34
Noninvasive Assessment of Myocardial Inflammation by Cardiovascular Magnetic Resonance in a Rat Model of Experimental Autoimmune Myocarditis
Summary-Myocarditis is defined as inflammation of myocardial tissue with characteristic inflammatory cellular infiltration into the myocardium. To date, reliable tools to noninvasively diagnose cellular inflammation in myocarditis are lacking. Here we demonstrate that the application of long-circulating magneto-fluorescent nanoparticles combined with cardiac magnetic resonance imaging permit noninvasive and robust imaging of myocardial inflammatory cellular infiltrates, enabling spatial mapping, quantification, and assessment of inflammation in experimental autoimmune myocarditis.
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Compared with clinically conventional cardiac magnetic resonance, magneto-fluorescent nanoparticle cardiac magnetic resonance more accurately detected scattered foci of inflammation and provided better conspicuity of small and less severe myocardial inflammation. Early and prompt diagnosis may lead to a paradigm shift in the therapeutic strategy of myocarditis. In addition, this magneto-fluorescent nanoparticle cardiac magnetic resonance approach could be an effective clinical application in monitoring the evolution of inflammation and response to antiinflammatory therapy in myocarditis.
Conclusions-Magneto-fluorescent nanoparticle cardiac magnetic resonance (CMR) permitted effective visualization of myocardial inflammatory cellular infiltrates and distinction of the extent of inflammation compared with conventional CMR in a preclinical model of experimental autoimmune myocarditis (EAM). Magnetofluorescent nanoparticle CMR performs best in EAM rats with at least moderate inflammatory response. 35
Cardioprotection Through S-Nitros(yl)ation of Macrophage Migration Inhibitory Factor
Summary-Macrophage migration inhibitory factor (MIF) is the first identified cytokine, discovered almost half a century ago by David, Bloom, and Bennett. Molecular knowledge about this protein mediator has recently grown tremendously, and a pivotal role has been attributed to MIF as a key regulator of innate and acquired immunity, as well as numerous pathophysiological functions involving its inflammatory cytokine and chemokine. There is emerging evidence that MIF also plays a central role in cardiovascular diseases and myocardial ischemia and reperfusion (I/R) injury. Despite an improved understanding of the pathophysiology of I/R injury and numerous preclinical trials, most of the clinical trials to prevent I/R injury have been disappointing. The present study now provides the first evidence that protein modification by means of S-nitros(yl)ation of MIF increases the cardioprotective properties of this factor in the early phase of I/R injury. This reveals the first-described posttranslational regulatory modification of MIF and thus opens up a novel role of this ancient protein. This study further identifies the precise site of this modification and uncovers a key function of the reactive cysteine 81 residue. S-nitros(yl)ation distinctly affects MIF properties and leads to decreased apoptosis and infarct size in vivo. Beyond the background that the precise pathophysiology of I/R injury is still not entirely understood, targeted regulation of MIF functions by S-nitros(yl)ation might deliver a new therapeutic approach in the treatment of myocardial infarction.
Conclusions-S-nitros(yl)ation of MIF is a pivotal novel regulatory mechanism, providing enhanced activity resulting in increased cytoprotection in myocardial reperfusion injury. 36
Activation of CD4 + T Lymphocytes Improves Wound Healing and Survival After Experimental Myocardial Infarction in Mice
Summary-Myocardial infarction is the leading cause of chronic heart failure syndrome, which still causes tremendous morbidity and mortality in the Western world. After myocardial infarction, heart failure results not only from a loss of contractile tissue but also from the remodeling of the remaining viable myocardium. Adverse remodeling often occurs despite optimal medical therapy and might originate from early dysfunctional wound healing. The pivotal role of activation of innate immunity during wound healing and remodeling of the remote myocardium after myocardial infarction has long been recognized. In this study, we present the first experimental data indicating that myocardial infarction induces activation of T lymphocytes. In particular, CD4 + T cells become activated on recognition of self-antigens during myocardial infarction and infiltrate both the infarcted and remote myocardium. CD4 + T-cell activation improves both wound healing and clinical outcome, because the genetically determined absence or inability of CD4 + T cells to recognize autoantigens results in impaired wound healing and impaired survival after myocardial infarction. Impaired collagenous scar formation is the most evident underlying cause of the clinical phenotype when CD4 + T cells are lacking or their activation is hampered. Our results might thus pave the way for the development of novel therapeutic protocols to modulate the adaptive immune response to myocardial injury.
Conclusions-
The present study provides the first evidence that CD4 + T cells become activated after MI, presumably driven by recognition of cardiac autoantigens, and facilitate wound healing of the myocardium. 37
MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension: Results of a Network Bioinformatics Approach
Summary-Pulmonary hypertension (PH) is a deadly disease with diverse etiologies resulting in pathological dysregulation in the pulmonary vasculature. This dysregulation involves numerous intersecting signaling pathways, the coordinate control of which may depend on master molecular effectors. MicroRNA molecules (miRNA) are small, noncoding RNA that may act as such regulators, but their importance in PH is still unclear. In the present study, a unique network biology-based approach was used to identify microRNA-21 (miR-21) as 1 of a select group of miRNA predicted to control expression of a convergent set of pathways in PH. Underscoring the biologic plausibility of this finding, miR-21 is upregulated by hypoxia and bone morphogenetic protein receptor 2 signaling, 2 important PH triggers. In turn, miR-21 targets an important vascular effector, RhoB, and induces molecular changes in pulmonary endothelial cells consistent with vasodilation and decreased angiogenesis. Furthermore, miR-21 is upregulated in lung from humans with PH and from multiple rodent models of PH. In 1 of these models, the genetic absence of miR-21 causes accelerated disease progression. Taken together, these data identify miR-21 as a coordinate regulator of PH pathology that acts as a homeostatic brake to stave off PH progression. This study reinforces the critical role for miRNA in PH and introduces the utility of a network-based method for identifying additional groups of disease-modifying miRNA. Because complex interactions among these miRNA with their common targets will dictate their individual impact on disease, the study of such miRNA networks may offer insight into their utility as therapeutic targets.
Conclusions-A network-based bioinformatic approach coupled with confirmatory in vivo data delineates a central regulatory role for miR-21 in PH. Furthermore, this study highlights the unique utility of network biology for identifying disease-modifying microRNA in PH. 38
Long-Term Effects of Sildenafil in a Rat Model of Chronic Mitral Regurgitation: Benefits of Ventricular Remodeling and Exercise Capacity
Summary-Mitral regurgitation (MR) induces chronic left ventricular volume overload and leads to left ventricular contractile dysfunction, heart failure, and, finally, death. Although surgical correction of MR, the only definitive cure, carries reasonably low mortality and morbidity risks,
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Most Read Articles on Studies in Animal Models e357 medical therapeutics have a role in many clinical situations such as in a patient population with greater surgical risk. However, there is currently no recommended pharmacological therapy for chronic MR. Despite previous efforts, medical therapies for chronic MR have produced disappointing and conflicting results. Since the early 2000s, sildenafil, part of a class of selective inhibitors of phosphodiesterase type 5, has been under intense study in various areas. Multiple lines of preclinical and clinical evidence support a therapeutic role for phosphodiesterase type 5 inhibition with sildenafil in the management of heart failure. Accordingly, we hypothesized that sildenafil may have a beneficial effect in chronic MR. The major findings of the present study are that sildenafil prevented left ventricular remodeling and exercise intolerance caused by chronic experimental MR. To our knowledge, this is the first study that shows that sildenafil is efficacious in the presence of MR. Additionally, we proposed potential mechanisms related to the effect of sildenafil: inhibition of inflammation and apoptosis. With consideration of the beneficial effects of sildenafil in MR rats, we can expect a therapeutic potential for sildenafil in patients with MR. Future clinical studies are needed.
Conclusions-Sildenafil significantly attenuates LV remodeling and prevents exercise intolerance in a rat model of chronic MR. This benefit may be associated with the antiapoptotic, anti-inflammatory effects of sildenafil. 39
Ischemic Conditioning Protects the Uremic Heart in a Rodent Model of Myocardial Infarction
Summary-Ischemic conditioning encompasses a number of established experimental techniques that provide powerful protection for an organ or vascular bed against ischemia/reperfusion injury. However, by and large, clinical trials have not delivered on the promise of preclinical studies undertaken in animals. A number of comorbid conditions such as diabetes mellitus and dyslipidemia have been demonstrated in animal models to attenuate the efficacy of ischemic conditioning. Up to one third of patients presenting with an acute coronary syndrome have chronic kidney disease. These patients have a particularly poor prognosis after acute myocardial infarction that has not been improved by enhanced reperfusion rates. Moreover, patients with chronic kidney disease are frequently excluded from clinical trials. The present study demonstrates that renal dysfunction per se is not a barrier to achieving substantial myocardial protection with ischemic preconditioning, remote ischemic preconditioning, and ischemic postconditioning. The survival pathways thought to be important in transducing the protective effect of ischemic preconditioning, remote ischemic preconditioning, and ischemic postconditioning appear to be preserved and activated to the same degree in 2 different models of experimental renal failure. This study provides the preclinical data to justify the inclusion of patients with chronic kidney disease in future clinical trials of ischemic conditioning as adjuvant therapy to reperfusion in the setting of acute myocardial infarction.
Conclusions-Conditioning strategies may present the best opportunity to improve outcomes for patients with chronic kidney disease after an acute coronary syndrome. 40
C/EBP Homologous Protein-10 (CHOP-10) Limits Postnatal Neovascularization Through Control of Endothelial Nitric Oxide Synthase Gene Expression
Summary-Understanding the molecular and cellular mechanisms involved in the regulation of vessel growth and maturation in the setting of tissue ischemia is of major importance and may trigger the development of innovative strategies of therapeutic angiogenesis in the treatment of ischemic diseases. In the present study, we analyzed the role of C/EBP homologous protein-10 (CHOP-10) in postischemic revascularization. CHOP-10 is a novel developmentally regulated nuclear protein that emerges as a critical transcriptional integrator among pathways regulating differentiation, proliferation, and survival. This study identifies CHOP-10 as a major modulator of vessel formation and maturation. The physiological significance of CHOP-10 in the vasculature is validated by the observation that ischemia and diabetes mellitus-induced oxidative stress upregulated CHOP-10 levels and that CHOP-10 deficiency markedly improved postischemic vessel growth in control animals but also in a pathological setting, such as diabetes mellitus. Finally, our data demonstrated that the transcriptional repression of endothelial nitric oxide synthase by CHOP-10 greatly contributes to the antiangiogenic effects of CHOP-10. In conclusion, this work suggests that CHOP-10 functions as an important regulator of postnatal neovascularization. Because downregulation of CHOP-10 promoted neovascularization, the regulation of CHOP-10 expression and activity may pave the way for new therapeutic strategies designed to increase vessel growth in the setting of ischemia. In contrast, forced expression or activation of CHOP-10 might limit unwanted neovascularization associated with tumor development or retinopathy.
Conclusions-This study identifies CHOP-10 as an important transcription factor modulating vessel formation and maturation. 41
Coronary Vasospasm Induced in Transgenic Mouse With Increased Phospholipase C-δ1 Activity
Summary-Coronary spasm is involved in the pathogenesis of not only variant angina, but the other acute coronary syndromes; however, its precise mechanism still remains unclear. We reported that phospholipase C (PLC)-δ1 activity in cultured skin fibroblasts obtained from patients with coronary spastic angina (CSA) was increased 3-fold compared with that from control subjects. We also detected R257H variant PLC-δ1 in CSA patients, which was associated with the increased PLC-δ1 enzymatic activity. We further found that p122 protein, a positive regulator of PLC-δ1, was upregulated in CSA patients. Thus, the increased PLC-δ1 activity caused by either structural mutation or increased positive regulator is likely to be related to the pathogenesis of coronary spasm. However, there has been no proof for a direct contribution of increased PLC-δ1 to enhanced coronary vasomotility. In this study, we generated transgenic mice with increased PLC-δ1 activity in vascular smooth muscle cells by overexpressing human R257H variant PLC-δ1. Our transgenic mouse showed increased PLC enzymatic activity in the coronary artery and enhanced coronary vasoconstrictor response to ergometrine compared with the wild-type mouse. In particular, intravenous ergometrine administration induced ST elevation on ECG and focal coronary artery narrowing such as that seen in CSA patients in the transgenic but not in the wild-type mouse. Thus, this transgenic mouse is a novel animal model of CSA and would provide a novel tool for revealing the mechanism for coronary spasm and investigating the treatment of CSA.
Conclusions-Increased PLC-δ1 activity enhances coronary vasomotility such as that seen in patients with coronary spastic angina. 42 
White Matter Protection in Congenital Heart Surgery
Summary-The most common neurological deficits in children after surgery for congenital heart disease are fine and gross motor deficits.
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Recent magnetic resonance imaging studies have demonstrated a significant number of newly developed white matter (WM) lesions in infants after surgery. The present study describes region-specific WM development in the juvenile porcine brain, which is similar in developmental stage to the human newborn. Acute and long-term cellular responses to cardiopulmonary bypass in oligodendrocyte lineages and neuron-axonal elements, which are the most prominent cell populations in WM, have been observed. A uniquely susceptible cellular target of cardiopulmonary bypass-induced WM injury in the oligodendrocyte lineage, as well as maturation-dependent vulnerability of developing WM, was found. Oligodendrocyte progenitor cells, which mediate WM recovery function, are highly resistant to cardiopulmonary bypass-induced injury. Interestingly, oligodendrocyte progenitor cell number decreases with age, which suggests that immature WM is vulnerable but also retains a significant endogenous cellular potential for recovery. Therefore, the optimal time window for congenital heart disease repair is the period during which WM contains the largest number of oligodendrocyte progenitor cells. Importantly, it was identified that under conditions of higher cerebral oxygenation and lower inflammation, the maturation stage was not a crucial determinant of cardiopulmonary bypass-induced WM injury. Together with the recent clinical finding that newborns with congenital heart disease have delayed brain development due to abnormal cerebral circulation in utero, the present study suggests that earlier normalization of cerebral circulation by primary congenital heart disease repair using higher cerebral oxygenation and lower inflammation should improve WM development in this population.
Conclusions-Primary repair in neonates and young infants potentially provides successful WM development in congenital heart disease patients. Cardiac surgery during this susceptible period should avoid ischemia-reperfusion injury and minimize inflammation to prevent long-term WM-related neurological impairment. 43
Gremlin Plays a Key Role in the Pathogenesis of Pulmonary Hypertension
Summary-Pulmonary hypertension is a disease characterized by pulmonary vascular remodeling and increased pulmonary vascular resistance. It occurs commonly in chronic hypoxic lung diseases and leads to increased morbidity and mortality. A major breakthrough in our understanding of pulmonary hypertension was achieved with the identification of heterozygous mutations in the bone morphogenetic receptor type 2 as the cause of the rare heritable form of pulmonary arterial hypertension. It was subsequently found that bone morphogenetic protein signaling was reduced in many other common forms of pulmonary hypertension, including hypoxic pulmonary hypertension. However, the mechanism underlying this reduction has not been clearly elucidated. Here, we report that gremlin, a secreted extracellular antagonist of bone morphogenetic proteins, was expressed more highly in pulmonary endothelial cells in vitro than in the endothelium of other organs and was markedly increased in response to hypoxia. We show that gremlin was increased selectively in the hypoxic mouse lung and that genetically manipulated mice with reduced gremlin expression showed attenuation of hypoxic pulmonary vascular remodeling and reduced pulmonary vascular resistance. Furthermore, we found that gremlin was increased in the small intrapulmonary vessels of lungs explanted from patients with pulmonary arterial hypertension. Thus, we have identified a novel mechanism contributing to the development of pulmonary hypertension, which, because it is an extracellular protein, represents an attractive potential therapeutic target.
Conclusions-These findings demonstrate a central role for increased gremlin in hypoxia-induced pulmonary vascular remodeling and the increased pulmonary vascular resistance in hypoxic pulmonary hypertension. High levels of basal gremlin expression in the lung may account for the unique vulnerability of the pulmonary circulation to heterozygous mutations of BMP type 2 receptor in pulmonary arterial hypertension. 44
Proteomics Analysis of Cardiac Extracellular Matrix Remodeling in a Porcine Model of Ischemia/Reperfusion Injury
Summary-By diverging from the traditional focus on intracellular proteins, we used a conceptually novel proteomics approach in which newly synthesized matrix proteins or loosely bound factors in the extracellular space were analyzed before the tissues were decellularized and integral extracellular matrix components were solubilized, which are not dissolved in conventional extraction buffers. By using this extraction procedure combined with state-of-the-art proteomics, we revealed novel extracellular matrix components in cardiac tissue and gained important insights into extracellular matrix remodeling by region and stage of fibrosis. Unlike any other proteomics study published to date, this extensive comparison allowed, for the first time, a coexpression analysis of extracellular matrix remodeling in a porcine model of myocardial ischemia/reperfusion injury. This biosignature of early-and late-stage remodeling may have clinical utility as prognostic markers. The novel extracellular matrix components identified in this study, and particularly those involved in the TGFβ regulatory pathway, may represent interesting modifiable targets for drug discovery.
Conclusions-Our findings reveal a biosignature of early-and latestage extracellular matrix remodeling after myocardial ischemia/ reperfusion injury, which may have clinical utility as a prognostic marker and modifiable target for drug discovery. 45
Downregulation of TMEM16A Calcium-Activated Chloride Channel Contributes to Cerebrovascular Remodeling During Hypertension by Promoting Basilar Smooth Muscle Cell Proliferation
Summary-During hypertension, cerebral arterioles undergo remodeling of the vascular walls, which contributes to the increased risk for stroke. Accumulating evidence suggests that chloride channels play an important role in regulation of cell cycle transition and cell proliferation and that the upregulation of volume-regulated chloride channel is involved in hypertension-induced cerebrovascular remodeling.
Recently, TMEM16A was proposed to be the molecular candidate of the calcium-activated chloride channel (CaCC). TMEM16A has been found to be abundantly expressed and to mediate the calciumactivated chloride current in several types of vascular smooth muscle cells. However, the molecular identity of CaCC and its functions in cerebrovascular smooth muscle cells remain enigmatic. In present study, we demonstrate that TMEM16A is responsible for the CaCC in rat basilar smooth muscle cells. The activity of CaCC in basilar smooth muscle cells is remarkably reduced in hypertensive rats. Upregulation of CaMKII activity and downregulation of TMEM16A expression contribute to the attenuation of CaCC in hypertension. In addition, TMEM16A negatively regulates cell proliferation and cell cycle transition from the G 0 /G 1 phase to the S phase through modifying cyclin D1 and cyclin E expression. These results provide evidence that the reduction of CaCC activity is an important contributor to hypertension-induced vascular smooth muscle cell proliferation and cerebrovascular remodeling, indicating that restoration of the TMEM16A CaCC activity could exert beneficial effects on hypertension-associated cardiovascular diseases such as stroke.
Conclusions-TMEM16A CaCC is a negative regulator of cell proliferation. Downregulation of CaCC may play an important role in hypertension-induced cerebrovascular remodeling, suggesting that modification of the activity of CaCC may be a novel therapeutic strategy for hypertension-associated cardiovascular diseases such as stroke. 46
Identification of a Monocyte-Predisposed Hierarchy of Hematopoietic Progenitor Cells in the Adventitia of Postnatal Murine Aorta
Summary-Leukocytes play diverse and critical roles in vascular biology and disease, including the development and progression of atherosclerosis. The source of leukocytes in the vascular wall has generally been considered to be remote tissues such as bone marrow or spleen via the peripheral circulation. This article presents new evidence that demonstrates that mature murine arteries contain resident stem and progenitor cells that are capable of forming hematopoietic colonies in culture and repopulating different types of blood cells after whole-body irradiation. These hematopoietic populations are strongly skewed toward monocyte/macrophage and lymphocyte lineages and are notably upregulated in proatherogenic mice. They are contained primarily among adventitial cells that express stem cell antigen-1, where they may be resident for prolonged periods, perhaps even constitutively. The presence of such stem and progenitor cells in the arterial adventitia provides a new paradigm to support the local origins of vascular leukocytes, in turn paving the way for a greater understanding of the regulation and involvement of inflammatory cells during vascular responses to acute and chronic injury. Ultimately, defining the role of these cells in human arteries in both health and disease may also provide new therapeutic opportunities to affect the evolution of different vascular disease processes, including atherosclerosis, aneurysm formation, vasculitis, ischemia, and malignancy.
Conclusions-The postnatal murine aorta contains rare multipotent hematopoietic progenitor/stem cells and is selectively enriched with stem cell antigen-1-positive monocyte/macrophage precursors. These populations may represent novel, local vascular sources of inflammatory cells. 47
Migraine Mutations Increase Stroke Vulnerability by Facilitating Ischemic Depolarizations
Summary-Our study establishes a mechanism that links migraine and stroke, 2 highly prevalent and debilitating diseases. Migraine is a well-recognized stroke risk factor. Although its prevalence is on par with other stroke risk factors such as diabetes mellitus and hypertension, there has been little insight into the mechanism of the migrainestroke association. Here, we present compelling evidence indicating that glutamatergic hyperexcitability associated with migraine mutations renders the brain more susceptible to ischemic depolarizations. As a result, the minimum critical level of blood flow required for tissue survival (ie, viability threshold) is elevated and infarction ensues, even in mildly ischemic tissues. This represents a paradigm shift in the search for a mechanism for increased stroke risk in migraineurs and differs radically from those previously postulated on the basis of clinical data alone. Our conclusions are based on optical and magnetic resonance imaging and electrophysiological recordings in transgenic mouse models for familial hemiplegic migraine type 1, a monogenic migraine syndrome (mutations in Ca v 2.1 channels) that has been a model for common but genetically complex forms of migraine based on shared clinical features, glutamatergic mechanisms, and elevated stroke risk. Clinical implications include a shorter therapeutic window for acute stroke interventions in migraineurs because of accelerated loss of potentially salvageable penumbra. Furthermore, migraine prophylaxis may reduce stroke risk by suppressing cerebral hyperexcitability, and antithrombotic prophylaxis may be indicated in susceptible migraineurs because they are more likely to have infarcts if and when they develop cerebral ischemic events.
Conclusions-We propose that enhanced susceptibility to ischemic depolarizations akin to spreading depression predisposes migraineurs to infarction during mild ischemic events, thereby increasing the stroke risk. 48
A 2b Adenosine Receptor Regulates Hyperlipidemia and Atherosclerosis
Summary-The Western high-fat diet has long been associated with obesity, elevation in circulating cholesterol and triglycerides, and altered metabolic disorders. The major problem or the ultimate outcome is some form of cardiac occlusion or atherosclerosis. Although numerous studies have shown the negative effect of high-fat, highcholesterol diets on the vasculature, including atherosclerosis and consequent mortality from occlusions of cardiac vessels, the general population would not change eating patterns to account for it. This has called for consideration of treatments that can potentially be used without a change in diet. Here, we used a genetically modified mouse model lacking the A 2b adenosine receptor and a specific agonist for this receptor, BAY 60-6583, to identify a new link between receptor expression/activation, lipidemia, and atherosclerosis. Our study showed augmented cholesterol and triglyceride levels and atherosclerosis in the knockout mice and a significant reduction in these parameters on treatment of wild-type mice with BAY 60-6583. Of importance, we observed a reduction in atherosclerosis across the aortic tree with this treatment while the mice were on a high-fat diet. We propose that activation of the A 2b adenosine receptor can be a therapeutic target that can reduce cholesterol and triglyceride levels and the progression of atherosclerosis without a significant change in the intake of a Western diet.
Conclusions-This study provides the first evidence that the A 2b AR regulates liver SREBP-1, hyperlipidemia, and atherosclerosis, suggesting that this receptor may be an effective therapeutic target. 49
Extramedullary Hematopoiesis Generates Ly-6C high Monocytes That Infiltrate Atherosclerotic Lesions
Summary-Atherosclerosis is an inflammatory disease characterized by the accumulation of lipids and leukocytes in the arterial wall.
Monocytes are large circulating leukocytes believed to be essential to the development and exacerbation of atherosclerosis. As disease worsens, the number of circulating monocytes rises, whereas in models with monocyte depletion, atherosclerosis neither develops nor evolves. It is believed that hematopoietic progenitors give rise to circulating monocytes exclusively in the bone marrow. These medullary monocytes circulate, accumulate in tissue, and differentiate to macrophages or dendritic cells. Extramedullary sites such as the spleen maintain reservoirs of undifferentiated monocytes that can exit en masse in response to acute inflammation. In this study, we show that during atherosclerosis the bone marrow outsources the production of monocytes to the spleen. These extramedullary monocytes accumulate in the growing atheromata. From a clinical perspective, this finding is important because it identifies the spleen as a possible biomarker organ and therapeutic target for cardiovascular disease, e360 Circulation October 22, 2013 and it proposes that inflammatory hematopoiesis could be targeted therapeutically in atherosclerosis.
Conclusions-Our findings indicate that extramedullary sites supplement the hematopoietic function of the bone marrow by producing circulating inflammatory cells that infiltrate atherosclerotic lesions. 50
Safety and Efficacy of Allogeneic Cell Therapy in Infarcted Rats Transplanted With Mismatched Cardiosphere-Derived Cells
Summary-Cardiosphere-derived cells (CDCs) are an attractive cell type for cardiomyoplasty after myocardial infarction, and autologous CDCs are already being tested clinically in the CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction (CADUCEUS) trial. Autologous therapy avoids immunologic rejection but necessitates patient-specific tissue harvesting, cell processing, and quality control, resulting in 3-to 6-week delays to therapy and possible variations in cell potency related to patient age and comorbidities. The use of universal donor (allogeneic) cells, if safe and effective, would obviate such limitations; however, immune rejection may limit effectiveness regardless of whether it poses safety hazards. Thus, we compared syngeneic and allogeneic CDC transplantation in infarcted rats from immunologically mismatched inbred strains. We demonstrate that allogeneic CDC therapy without immunosuppression is safe and induces only a mild transient local response without signs of systemic immunogenicity. Despite lower long-term engraftment compared with syngeneic cells, allogeneic CDCs produce similar structural and functional beneficial effects (which persist at least 6 months after transplantation). The benefits are due to stimulation of endogenous repair mechanisms and regrowth of recipient heart tissue rather than formation of new donor-derived myocardium. In practice, the present work opens up a new treatment paradigm: CDCs could be grown in large numbers from allogeneic heart tissue in a central facility under strict quality control and banked for future use, enabling safe and effective myocardial repair in a timely, cost-efficient manner. This work motivates the testing of allogeneic human CDCs as a potential clinical product for cellular cardiomyoplasty.
Conclusions-Allogeneic CDC transplantation without immunosuppression is safe, promotes cardiac regeneration, and improves heart function in a rat myocardial infarction model, mainly through stimulation of endogenous repair mechanisms. The indirect mechanism of action rationalizes the persistence of benefit despite the evanescence of transplanted cell survival. This work motivates the testing of allogeneic human CDCs as a potential off-the-shelf product for cellular cardiomyoplasty. 51 
